From radiation oncology to proton therapy
Radiation oncology has witnessed remarkable technological advancements in recent years. As radiation oncologists, there is a continuous drive to explore new modalities and improve treatment outcomes. The introduction of proton therapy has opened new possibilities to deliver radiation for cancer treatment.
Dr. Kasper emphasizes that proton therapy is not just another treatment modality; it represents a paradigm shift in how radiation can be delivered. The precision of proton therapy allows for targeted treatment, minimizing damage to surrounding healthy tissues. This is particularly crucial when treating complex cancer cases, such as tumors located in sensitive areas like the spine and base of the skull.
Discover how IBA’s ProteusONE advanced capabilities help treat complex cases here.
IBA’s ProteusONE remarkable capabilities
ProteusONE stands out as a versatile and powerful tool for oncologists, designed to tackle some of the most challenging indications in cancer treatment. Dr. Kasper notes that they will primarily use ProteusONE to focus on complex cases, such as spine and skull tumors, CNS tumors, as well as head and neck, prostate, and breast cancers. The remarkable capabilities of ProteusONE will allow the Lynn Cancer Institute to participate in clinical trials and push the boundaries of what is achievable in cancer treatment. This commitment to research underscores the institute's dedication to delivering cutting-edge cancer care.
Choosing the right proton therapy partner: IBA
When selecting a partner for their proton therapy initiatives, the Lynn Cancer Institute prioritized international presence, reliability and a proven track record. Dr. Kasper explains that their choice to collaborate with IBA was driven by the company’s extensive experience and commitment to innovation in proton therapy.
The institute sought a long-term partnership, viewing their relationship with IBA as a “marriage.” This perspective highlights the importance of trust and collaboration in advancing cancer care. Dr. Kasper expresses confidence in IBA’s roadmap for future developments, ensuring the institute can upgrade its capabilities as new technologies emerge.
Click here to find out more about IBA’s commitment to ensuring their partner’s successful proton therapy project implementation and cancer patient care.
ProteusONE as a best-in-class solution
Dr. Kasper and his team were particularly impressed with the wide-ranging capabilities of the ProteusONE system. Its throughput and adaptability make it a significant asset in their treatment arsenal. The institute is also excited about upcoming innovations, such as DynamicARC®* and ConformalFLASH®*, which promise to enhance the precision and efficiency of proton therapy. These advancements align with the Lynn Cancer Institute's goal of providing the best possible care to its patients.
Discover IBA’s commitment to creating the future of proton therapy innovations with DynamicARC* and ConformalFLASH*.
Community Support and Responsibility
As the Proton Therapy Center at the Lynn Cancer Institute is entirely funded by community philanthropy, Dr. Kasper acknowledges the tremendous responsibility of managing the resources. The choice of IBA as their proton therapy partner was aligned with the center’s commitment to being excellent stewards of the funds entrusted to them and delivering exceptional cancer patient care.
Notes
Disclaimer: The statements of the healthcare professional included in this testimonial reflect only his opinion and personal experience. They do not necessarily reflect the opinion of any institution with whom he is affiliated or IBA.
* ConformalFLASH & DynamicARC are registered brands of IBA’s Proton Therapy which are currently under research and development. ConformalFLASH and DynamicARC will be available for sale when regulatory clearance is received. Due to a continuous research and development program, IBA reserves the right to make changes in design, technical descriptions, and specifications of its products without prior notice. Some features are under development and may be subject to review by competent authorities.
